Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: A proposal for clinical application

Endocrine-Related Cancer

Volumn 12, Issue 2, 2005, Pages 305-317

  Saggiorato, E ^a   De Pompa, R ^a   Volante, M ^a   Cappia, S ^a   Arecco, F ^a   Dei Tos, A P ^b   Orlandi, F ^a   Papotti, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Regional Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYTOKERATIN 19; GALECTIN 3; HBME 1 ANTIGEN; KERATAN SULFATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 373E1; MONOCLONAL ANTIBODY 47; MONOCLONAL ANTIBODY 9C4; MONOCLONAL ANTIBODY B170; MONOCLONAL ANTIBODY HBME 1; PEROXIDASE; THYROID PEROXIDASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; THYROID ADENOMA; THYROID FOLLICLE; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; BIOPSY, FINE-NEEDLE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 21244455609     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00944     Document Type: Article

References (67)

1. Baloch ZW & LiVolsi VA 2002 The quest for a magic tumor marker: continuing saga in the diagnosis of the follicular lesions of thyroid. American Journal of Clinical Pathology 118 165-166.
2. Baloch ZW, Tam D, Langer J, Mandel S, LiVolsi VA & Gupta PK 2000 Ultrasound-guided fine-needle aspiration biopsy of the thyroid: role of on-site assessment and multiple cytologic preparations. Diagnostic Cytopathology 23 425-429.
3. Baloch ZW, Fleisher S, LiVolsi VA & Gupta PK 2002 Diagnosis of 'follicular neoplasm': a gray zone in thyroid fine-needle aspiration cytology. Diagnostic Cytopathology 26 41-44.
4. Barondes SH, Cooper DN, Gitt MA & Leffler H 1994 Galectins. Structure and function of a large family of animal lectins. Journal of Biological Chemistry 269 20807-20810.
5. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R & Larsson O 2001 Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357 1644-1650.
6. Bartolazzi A, Papotti M & Orlandi F 2003 Methodological considerations regarding the use of galectin-3 expression analysis in preoperative evaluation of thyroid nodules. Journal of Clinical Endocrinology and Metabolism 88 950.
7. Beesley MF & McLaren KM 2002 Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 41 236-243.
8. Castro MR & Gharib H 2003 Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls. Endocrine Practice 9 128-136.
9. Cheung CC, Carydis B, Ezzat S, Bedard YC & Asa SL 2001a Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. Journal of Clinical Endocrinology and Metabolism 86 2187-2190.
10. Cheung CC, Ezzat S, Freeman JL, Rosen IB & Asa SL 2001b Immunohistochemical diagnosis of papillary thyroid carcinoma. Modern Pathology 14 338-342.
11. Chiappetta G, Tallini G, De Biasio MC, Manfioletti G, Martinez-Tello FJ, Pentimalli F, de Nigris F, Mastro A, Botti G, Fedele M, Berger N, Santoro M, Giancotti V & Fusco A 1998 Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Research 58 4193-4198.
12. Christensen L, Blichert-Toft M, Brandt M, Lange M, Sneppen SB, Ravnsbaek J, Mollerup CL, Strange L, Jensen F, Kirkegaard J, Sand Hansen H, Sorensen SS & Feldt-Rasmussen U 2000 Thyroperoxidase (TPO) immunostaining of the solitary cold thyroid nodule. Clinical Endocrinology 53 161-169.
13. Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D & Westra WH 2004 Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clinical Cancer Research 10 2761-2765.
14. DeLellis RA, Lloyd RV, Heitz PhU & Eng C 2004 Pathology and genetics of tumours of the endocrine organs. In World Health Organization Classification of Tumours, pp 49-133. Eds P Kleihues & LH Sobin. Lyon: IARC.
15. De Micco C, Ruf J, Chrestian MA, Gros N, Henry JF & Carayon P 1991 Immunohistochemical study of thyroid peroxidase in normal, hyperplastic, and neoplastic human thyroid tissues. Cancer 67 3036-3041.
16. Di Orio F 1994 Caratteristiche del test diagnostico. In Elementi di Metodologia Epidemiologica Clinica, pp 64-65. Eds F Carle, A Mattel, S Necozione & F Di Orio. Padova: Piccin.
17. Fernandez PL, Merino MJ, Gomez M, Campo E, Medina T, Castronovo V, Sanjuan X, Cardesa A, Liu FT & Sobel ME 1997 Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. Journal of Pathology 181 80-86.
18. Fonseca E, Nesland JM, Hoie J & Sobrinho-Simoes M 1997 Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins. Virchows Archiv 430 239-245.
19. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG & Bartolazzi A 1999 Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. Journal of Clinical Oncology 17 3494-3502.
20. Harms H, Hofmann M & Ruschenburg I 2002 Fine needle aspiration of the thyroid: can an image processing system improve differentiation? Analytical and Quantitative Cytology and Histology 24 147-153.
21. Haugen BR, Woodmansee WW & McDermott MT 2002 Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours. Clinical Endocrinology 56 281-290.
22. Hegedus L, Bonnema SJ & Bennedbaek FN 2003 Management of simple nodular goiter: current status and future perspectives. Endocrine Reviews 24 102-132.
23. Henry JF, Denizot A, Porcelli A, Villafane M, Zoro P, Garcia S & De Micco C 1994 Thyroperoxidase immunodetection for the diagnosis of malignancy on fine-needle aspiration of thyroid nodules. World Journal of Surgery 18 529-5 34.
24. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM & Baloch ZW 2002 Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Archives of Patholology and Laboratory Medicine 126 710-713.
25. van Hoeven KH, Kovatich AJ & Miettinen M 1998 Immunocytochemical evaluation of HBME-1, CA 19-19 and CD-15 (Leu-MI) in fine-needle aspirates of thyroid nodules. Diagnostic Cytopathology 18 93-97.
26. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A & Kubo T 1999 Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85 2475-2484.
27. Khurana KK, Truong LD, LiVolsi VA & Baloch ZW 2003 Cytokeratin 19 immunolocalization in cell block preparation of thyroid aspirates. An adjunct to fine-needle aspiration diagnosis of papillary thyroid carcinoma. Archives of Patholology and Laboratory Medicine 127 579-583.
28. Kini SR 1987 Thyroid. In Guides to Clinical Aspiration Biopsy, edn 1, pp 143-146. Ed. TS Kline. New York: Igaku-Shoin.
29. Liou MJ, Chan EC, Lin JD, Liu FH & Chao TC 2003 Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. Cancer Letters 191 223-227.
30. Liu FT, Patterson RJ & Wang JL 2002 Intracellular functions of galectins. Biochimica et Biophysica Acta 1572 263-273.
31. Lloyd RV 2001 Distinguishing benign from malignant thyroid lesions: galectin 3 as the latest candidate. Endocrine Pathology 12 255-257.
32. Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, DeLellis RA, Harach HR, Kakudo K, LiVolsi VA, Rosai J, Sebo TJ, Sobrinho-Simoes M, Wenig BM & Lae ME 2004 Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. American Journal of Surgery and Pathology 28 1336-1340.
33. Magro G, Perissinotto D, Schiappacassi M, Goletz S, Otto A, Muller EC, Bisceglia M, Brown G, Ellis T, Grasso S, Colombatti A & Perris R 2003 Proteomic and postproteomic characterization of keratan sulfate-glycanated isoforms of thyroglobulin and transferrin uniquely elaborated by papillary thyroid carcinomas. American Journal of Pathology 163 183-196.
34. Mai KT, Bokhary R, Yazdi HM, Thomas J & Commons AS 2002 Reduced HBME-I immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hurthle cell and/or apocrine-like changes. Histopathology 40 133-142.
35. Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU & Kimura ET 2002 Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. Journal of Clinical Endocrinology and Metabolism 87 4806-4810.
36. Mazzaferri EL 1993 Management of a solitary thyroid nodule. New England Journal of Medicine 328 553-559.
37. Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR & Lennard TW 2004 Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 45 493-500.
38. Miettinen M & Karkkainen P 1996 Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Virchows Archiv 429 213-219.
39. Miettinen M, Kovatich AJ & Karkkainen P 1997 Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications. Virchows Archiv 431 407-413.
40. Nascimento MC, Bisi H, Alves VA, Longatto-Filho A, Kanamura CT & Medeiros-Neto G 2001 Differential reactivity for galectin-3 in Hurthle cell adenomas and carcinomas. Endocrine Pathology 12 275-279.
41. Niedziela M, Maceluch J & Korman E 2002 Galectin-3 is not a universal marker of malignancy in thyroid nodular disease in children and adolescents. Journal of Clinical Endocrinology and Metabolism 87 4411-4415.
42. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, Kroll TG & Nikiforov YE 2003 RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. Journal of Clinical Endocrinology and Metabolism 88 2318-2326.
43. Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, De Giuli P & Angeli A 1998 Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Research 58 3015-3020.
44. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, Panunzi C, Rinaldi R, Toscano V & Pacella CM 2002 Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. Journal of Clinical Endocrinology and Metabolism 87 1941-1946.
45. Papotti M, Volante M, Saggiorato E, Deandreis D, Veltri A & Orlandi F 2002 Role of galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma. European Journal of Endocrinology 147 515-521.
46. Porter RM & Lane EB 2003 Phenotypes, genotypes and their contribution to understanding keratin function. Trends in Genetics 19 278-285.
47. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A & Kloos RT 2004 Galectin-3, fibronectin-1, CITED-1, HBME-1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Modern Pathology 18 48-57.
48. Raffaelli M, De Micco C, Lubrano D & Henry JF 2001 Immunodetection of thyroid peroxidase in the diagnosis of follicular variants of thyroid papillary cancer. Annales deChirurge 126 148-151.
49. Raphael SJ, McKeown-Eyssen G & Asa SL 1994 High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors. Modern Pathology 7 295-300.
50. Ringel MD 2000 Molecular diagnostic tests in the diagnosis and management of thyroid carcinoma. Reviews in Endocrine & Metabolic Disorders 1 173-181.
51. Sack MJ, Astengo-Osuna C, Lin BT, Battifora H & LiVolsi VA 1997 HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Modern Pathology 10 668-674.
52. Saggiorato E, Cappia S, De Giuli P, Mussa A, Pancani G, Caraci P, Angeli A & Orlandi F 2001 Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 86 5152-5158.
53. Saggiorato E, Aversa S, Deandreis D, Arecco F, Mussa A, Puligheddu B, Cappia S, Conticello S, Papotti M & Orlandi F 2004 Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. Journal of Endocrinological Investigation 27 311-317.
54. Sahoo S, Hoda SA, Rosai J & DeLellis RA 2001 Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. American Journal of Clinical Pathology 116 696-702.
55. Saji M, Xydas S, Westra WH, Liang CK, Clark DP, Udelsman R, Umbricht CB, Sukumar S & Zeiger MA 1999 Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms. Clinical Cancer Research 5 1483-1489.
56. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F & Santoro M 2004 Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 89 5175-5180.
57. Schröder S, Wodzynski A & Padberg B 1996 Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies. Pathologe 17 425-432.
58. Serini G, Trusolino L, Saggiorato E, Cremona O, De Rossi M, Angeli A, Orlandi F & Marchisio PC 1996 Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue. Journal of the National Cancer Institute 88 442-449.
59. Sheibani K, Esteban JM, Bailey A, Battifora H & Weiss LM 1992 Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Human Pathology 23 107-116.
60. Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K & Amino N 2003 Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors. Cancer Letters 199 69-73.
61. Tangpricha V, Chen BJ, Swan NC, Sweeney AT, de las Morenas A & Safer JD 2001 Twenty-one-gauge needles provide more cellular samples than twenty-five-gauge needles in fine-needle aspiration biopsy of the thyroid but may not provide increased diagnostic accuracy. Thyroid 11 973-976.
62. Volante M, Bozzalla-Cassione F, DePompa R, Saggiorato E, Bartolazzi A, Orlandi F & Papotti M 2004a Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Archiv 445 183-188.
63. Volante M, Bozzalla-Cassione F, Orlandi F & Papotti M 2004b Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Archiv 444 309-312.
64. Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS & Haugen BR 2004 The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. American Journal of Clinical Pathology 122 524-531.
65. Xu XC, el-Naggar AK & Lotan R 1995 Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. American Journal of Pathology 147 815-822.
66. Yang GC, Liebeskind D & Messina AV 2003 Should cytopathologists stop reporting follicular neoplasms on fine-needle aspiration of the thyroid? Cancer 99 69-74.
67. Yang RY & Liu FT 2003 Galectins in cell growth and apoptosis. Cellular and Molecular Life Sciences 60 267-276.